CU20200053A7 - Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación - Google Patents

Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación

Info

Publication number
CU20200053A7
CU20200053A7 CU2020000053A CU20200053A CU20200053A7 CU 20200053 A7 CU20200053 A7 CU 20200053A7 CU 2020000053 A CU2020000053 A CU 2020000053A CU 20200053 A CU20200053 A CU 20200053A CU 20200053 A7 CU20200053 A7 CU 20200053A7
Authority
CU
Cuba
Prior art keywords
inhibitor
crystalline form
janocinases
composition
preparation process
Prior art date
Application number
CU2020000053A
Other languages
English (en)
Other versions
CU24671B1 (es
Inventor
Gary E L Brandt
Marta Dabros
Ryan Hudson
Jennifer Kozak
Robert Murray Mckinnell
Jerry Nzerem
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CU20200053A7 publication Critical patent/CU20200053A7/es
Publication of CU24671B1 publication Critical patent/CU24671B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

<p>La invención proporciona un compuesto de Ia fórmula (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>o una sal farmacéuticamente aceptable de este, que es un inhibidor de las janocinasas (JAK), composiciones farmaceúticas que comprenden dicho compuesto y una forma cristalina, útiles para tratar enfermedades inflamatorias de Ia piel y otras enfermedades. La invención también proporciona procesos y productos intermedios útiles para preparar dicho compuesto.</p>
CU2020000053A 2017-10-27 2018-10-26 Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación CU24671B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
CU20200053A7 true CU20200053A7 (es) 2021-03-11
CU24671B1 CU24671B1 (es) 2023-07-12

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000053A CU24671B1 (es) 2017-10-27 2018-10-26 Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación

Country Status (37)

Country Link
US (6) US10308646B2 (es)
EP (1) EP3672965B1 (es)
JP (1) JP7218364B2 (es)
KR (1) KR102613503B1 (es)
CN (1) CN111247142B (es)
AR (1) AR113803A1 (es)
AU (1) AU2018354370B2 (es)
BR (1) BR112020008015A2 (es)
CA (1) CA3074034A1 (es)
CL (1) CL2020001090A1 (es)
CR (1) CR20200180A (es)
CU (1) CU24671B1 (es)
DK (1) DK3672965T3 (es)
DO (1) DOP2020000083A (es)
EA (1) EA202091016A1 (es)
EC (1) ECSP20023795A (es)
ES (1) ES2932526T3 (es)
GE (1) GEP20227344B (es)
HR (1) HRP20221221T1 (es)
HU (1) HUE060401T2 (es)
IL (1) IL274037B2 (es)
LT (1) LT3672965T (es)
MA (1) MA49956B1 (es)
MD (1) MD3672965T2 (es)
MX (1) MX2020004255A (es)
NI (1) NI202000032A (es)
PE (1) PE20201495A1 (es)
PH (1) PH12020500528A1 (es)
PL (1) PL3672965T3 (es)
PT (1) PT3672965T (es)
RS (1) RS63608B1 (es)
SG (1) SG11202001706RA (es)
SI (1) SI3672965T1 (es)
TW (1) TWI789446B (es)
UA (1) UA125130C2 (es)
WO (1) WO2019084383A1 (es)
ZA (1) ZA202001641B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102613503B1 (ko) 2017-10-27 2023-12-13 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用
AR118768A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Derivados de pirimidina como inhibidores de las cinasas jak
EP3959213A1 (en) 2019-04-24 2022-03-02 Theravance Biopharma R&D IP, LLC Pyrimidine jak inhibitors for the treatment of skin diseases
AU2021318201A1 (en) * 2020-07-28 2023-02-02 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
IL300906A (en) * 2020-08-26 2023-04-01 Nalo Therapeutics Modulators of MYC family proto-oncogene proteins
EP4225438A1 (en) * 2020-10-08 2023-08-16 Icahn School of Medicine at Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
EP1831216A2 (en) * 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
BR112014015549A8 (pt) 2011-12-22 2017-07-04 Hoffmann La Roche composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
CN106687467A (zh) * 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法
EP3303348B1 (en) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
EP3347097B1 (en) * 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
KR102244257B1 (ko) 2016-04-28 2021-04-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
KR102613503B1 (ko) * 2017-10-27 2023-12-13 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
AR118768A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Derivados de pirimidina como inhibidores de las cinasas jak
EP3959213A1 (en) 2019-04-24 2022-03-02 Theravance Biopharma R&D IP, LLC Pyrimidine jak inhibitors for the treatment of skin diseases

Also Published As

Publication number Publication date
MA49956B1 (fr) 2022-11-30
JP7218364B2 (ja) 2023-02-06
US10562894B2 (en) 2020-02-18
SI3672965T1 (sl) 2022-11-30
PL3672965T3 (pl) 2023-01-16
US11420965B2 (en) 2022-08-23
US10988470B2 (en) 2021-04-27
MD3672965T2 (ro) 2022-12-31
CR20200180A (es) 2020-08-12
HRP20221221T1 (hr) 2022-12-09
DK3672965T3 (da) 2022-10-03
GEP20227344B (en) 2022-01-25
TWI789446B (zh) 2023-01-11
SG11202001706RA (en) 2020-03-30
UA125130C2 (uk) 2022-01-12
ZA202001641B (en) 2021-04-28
KR102613503B1 (ko) 2023-12-13
CN111247142B (zh) 2022-12-02
CA3074034A1 (en) 2019-05-02
IL274037A (en) 2020-06-30
PT3672965T (pt) 2022-09-29
US20190127364A1 (en) 2019-05-02
JP2021501151A (ja) 2021-01-14
LT3672965T (lt) 2022-10-10
US10774080B2 (en) 2020-09-15
KR20200078517A (ko) 2020-07-01
NI202000032A (es) 2020-10-09
US20200140430A1 (en) 2020-05-07
US20220396573A1 (en) 2022-12-15
EP3672965B1 (en) 2022-09-07
US20210214349A1 (en) 2021-07-15
RS63608B1 (sr) 2022-10-31
EA202091016A1 (ru) 2020-07-17
US20200369660A1 (en) 2020-11-26
US20190241555A1 (en) 2019-08-08
AU2018354370B2 (en) 2023-04-27
AU2018354370A1 (en) 2020-04-09
BR112020008015A2 (pt) 2020-10-27
AR113803A1 (es) 2020-06-10
MA49956A (fr) 2020-07-01
DOP2020000083A (es) 2020-08-15
US11814377B2 (en) 2023-11-14
CU24671B1 (es) 2023-07-12
WO2019084383A1 (en) 2019-05-02
EP3672965A1 (en) 2020-07-01
PH12020500528A1 (en) 2021-06-07
IL274037B1 (en) 2023-07-01
ES2932526T3 (es) 2023-01-20
IL274037B2 (en) 2023-11-01
TW201930304A (zh) 2019-08-01
CN111247142A (zh) 2020-06-05
US10308646B2 (en) 2019-06-04
CL2020001090A1 (es) 2020-08-21
ECSP20023795A (es) 2020-06-30
HUE060401T2 (hu) 2023-02-28
PE20201495A1 (es) 2020-12-29
MX2020004255A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
CU20200053A7 (es) Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2020001469A2 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201791576A1 (ru) Ингибитор jak
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
PH12021550388A1 (en) Process for preparing jak inhibitors and intermediates thereof
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы